Tranexamic acid
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1986
- First approval year
- 1986
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tranexamic acid
- Molecular weight
- 157.21
- Structure (SMILES)
- NC[C@H]1CC[C@H](C(=O)O)CC1
- cyklo f heavy period relief
- Cyklo-f heavy period relief
- cyklokapron
- Cyklokapron
- exacyl
- Exacyl
- lysteda
- Lysteda
- menstralite
- Menstralite
- tranexamic acid
- Tranexamic acid
- 1 5g intravenous exacyl
- 1 gram Tranexamic Acid (TXA)
- 1 gram tranexamic acid txa
- 1.5g intravenous Exacyl
- acide tranexamique
- Acide tranexamique
- Acide Tranexamique
- acido tranexamico
- Acido tranexamico
- Active comparator : Tranexamic Acid (Exacyl)
- active comparator tranexamic acid exacyl
- amcha
- Amcha
- apcc apcc txa
- cl 65336
- CL 65336
- CL-65336
- cl65336
- CL65336
- Conventional Oral TXA (Tranexamic Acid)
- conventional oral txa tranexamic acid
- cyclo f
- Cyclo-f
- cyclocapron
- Cyclocapron
And 161 more, listed on the interactive page.
- ATC classification codes
- B02AA02
Sources for recorded values
- CAS registry numbers
- 1197-18-8
- ChEMBL ID
- CHEMBL877
- InChIKey
- GYDJEQRTZSCIOI-LJGSYFOKSA-N
- RxNorm IDs (RxCUI)
- 10691
- FDA ingredient codes (UNII)
- 6T84R30KC1
- Applicant
- PFIZER
- Approval date
- 30 Dec 1986
- Application number
- NDA019281
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- tranexamic acid
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Binding
- Action type
- Binding
- Target
- plasminogen
- Gene symbol
- PLG
- Protein identifier
- P00747
- Median affinity
- 3.6
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Plasminogen inhibitor
- Action type
- Inhibitor
- Target
- Plasminogen
- Protein identifier
- P00747
Open Targets mechanisms
- Mechanism
- Plasminogen inhibitor
- Action type
- Inhibitor
- Target
- Plasminogen
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- PLG
- Protein identifier
- P00747
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Astrocytoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Wounds and Injuries
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Subarachnoid Hemorrhage
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000713
- Subject identifier
- D013345
- Condition
- Leiomyoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000731
- Subject identifier
- D007889
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Liver Cirrhosis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0001422
- Subject identifier
- D008103
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001642
- Subject identifier
- D019337
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Spinal Cord Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003828
- Subject identifier
- D013120
- Condition
- Brain Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003833
- Subject identifier
- D001932
- Condition
- Pain
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Epistaxis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003895
- Subject identifier
- D004844
- Condition
- Fractures, Bone
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003931
- Subject identifier
- D050723
- Condition
- Melanosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003963
- Subject identifier
- D008548
- Condition
- Hip Fractures
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003964
- Subject identifier
- D006620
- Condition
- Skin Neoplasms
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0004198
- Subject identifier
- D012878
- Condition
- Aortic Aneurysm, Abdominal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004214
- Subject identifier
- D017544
- Condition
- Anemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004272
- Subject identifier
- D000740
- Condition
- Scoliosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004273
- Subject identifier
- D012600
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004284
- Subject identifier
- D006258
- Condition
- Osteoarthritis, Knee
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004616
- Subject identifier
- D020370
- Condition
- Pelvic Organ Prolapse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004710
- Subject identifier
- D056887
- Condition
- Hypotension
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0005251
- Subject identifier
- D007022
- Condition
- Cerebral Hemorrhage
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005669
- Subject identifier
- D002543
And 39 more, listed on the interactive page.
- Condition identifier
- EFO_0000284
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000551
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000713
- Condition identifier
- EFO_0000731
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001422
- Condition identifier
- EFO_0001642
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002950
- Condition identifier
- EFO_0003828
- Condition identifier
- EFO_0003833
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003881
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003895
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003895
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003931
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003963
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003964
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004198
- Condition identifier
- EFO_0004214
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004273
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004284
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004352
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004616
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004710
- Highest recorded phase
- 3
And 121 more, listed on the interactive page.
- Event
- acute generalised exanthematous pustulosis
- Reports
- 13
- Reporting signal score
- 18.9047
- Event
- acute myocardial infarction
- Reports
- 31
- Reporting signal score
- 42.8755
- Event
- anaphylactic reaction
- Reports
- 63
- Reporting signal score
- 86.133
- Event
- anaphylactic shock
- Reports
- 28
- Reporting signal score
- 40.4632
- Event
- angioedema
- Reports
- 26
- Reporting signal score
- 16.7004
- Event
- asthenia
- Reports
- 3
- Reporting signal score
- 18.776
- Event
- blood pressure decreased
- Reports
- 30
- Reporting signal score
- 27.6611
- Event
- cerebral infarction
- Reports
- 21
- Reporting signal score
- 23.6083
- Event
- cerebral venous sinus thrombosis
- Reports
- 6
- Reporting signal score
- 21.5197
- Event
- coronary artery thrombosis
- Reports
- 10
- Reporting signal score
- 28.3152
- Event
- deep vein thrombosis
- Reports
- 56
- Reporting signal score
- 62.0821
- Event
- diarrhoea
- Reports
- 7
- Reporting signal score
- 30.557
- Event
- drug hypersensitivity
- Reports
- 1
- Reporting signal score
- 20.4824
- Event
- fall
- Reports
- 3
- Reporting signal score
- 17.8469
- Event
- false negative investigation result
- Reports
- 5
- Reporting signal score
- 19.8954
- Event
- fatigue
- Reports
- 3
- Reporting signal score
- 44.0037
- Event
- generalised tonic-clonic seizure
- Reports
- 25
- Reporting signal score
- 42.2017
- Event
- grand mal convulsion
- Reports
- 45
- Reporting signal score
- 113.174
- Event
- haemoglobin decreased
- Reports
- 38
- Reporting signal score
- 18.8101
- Event
- haemoglobin increased
- Reports
- 16
- Reporting signal score
- 43.588
- Event
- haemorrhage
- Reports
- 54
- Reporting signal score
- 59.2114
- Event
- hypotension
- Reports
- 59
- Reporting signal score
- 22.666
- Event
- ischaemic stroke
- Reports
- 21
- Reporting signal score
- 26.7
- Event
- melaena
- Reports
- 37
- Reporting signal score
- 61.0184
- Event
- myoclonic epilepsy
- Reports
- 12
- Reporting signal score
- 39.8546
And 20 more, listed on the interactive page.
- NCT00113568
- NCT00375258
- NCT00386308
- NCT00401193
- NCT00670345
- NCT00809393
- NCT01085006
- NCT01136590
- NCT01141127
- NCT01228136
- NCT01295294
- NCT01338454
- NCT01530399
- NCT01622946
- NCT01643135
- NCT01846507
- NCT01866943
- NCT01881568
- NCT01895101
- NCT01937559
- NCT02086500
- NCT02094066
- NCT02117128
- NCT02153593
- NCT02219152
And 174 more, listed on the interactive page.
- Dose
- 10 mg/kg
- Route
- Intravenous
- How often
- 3 to 4 times daily for 2 to 8 days, immediately before tooth extraction
Conditions of use
- Infuse no more than 1 mL/minute to avoid hypotension
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 63.32
- Calculated partition coefficient (ALogP)
- 0.84
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 11
- Molecular formula
- C8H15NO2
- Natural product
- Yes
- 0013-1114
- 0591-3720
- 14593-318
- 14789-115
- 23155-166
- 23155-524
- 23155-909
- 23155-910
- 25021-415
- 25021-418
- 42571-189
- 42571-314
- 43066-008
- 50268-772
- 55150-188
- 59651-839
- 60687-750
- 62559-265
- 65145-106
- 65219-534
- 67457-197
- 68083-160
- 68083-613
- 69918-301
- 71357-017
And 25 more, listed on the interactive page.
These details could not be displayed.
Related records
Trials (679)
- "Topical Tranexamic Acid With Flap Fixation: A Novel Approach to Minimize Post-operative Drainage and Surgical Site Infection in Patients Undergoing Modified Radical Mastectomy"
- A Clinical Observation of 1064-nm Q-Switched Fractional Laser Combined With Oral Tranexamic Acid on Treating of Melasma.
- A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
- A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery
- A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery
- A Randomized Comparison of Two Doses of Tranexamic Acid in Open-Heart Surgery
- A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery
- A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
- A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
- A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population
- A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
- A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
- A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
- A Study to Evaluate the Safety, Tolerability and Efficacy of LB1148 for Subjects Undergoing Elective Bowel Resection
- A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement
- Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty
- ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
- Adjuvant Tranexamic Acid (TXA) Versus Surgery Alone for Adult Patients With Chronic Subdural Hematoma (CSDH)
- Alteration of Thrombelastography and Coagulation Function in Patients Undergoing Total Knee Arthroplasty With Intra-articular Tranexamic Acid Administration
Approved for (1)
In development for (57)
- Abdominal aortic aneurysm Phase 3
- Anemia Phase 3
- Aortic aneurysm Phase 3
- Arthropathy Phase 3
- Astrocytoma (excluding glioblastoma) Phase 3
- Blood coagulation disease Phase 3
- Bone cancer Phase 3
- Bone fracture Phase 3
- Brain injury Phase 3
- Brain neoplasm Phase 3
- Burn Phase 3
- Cancer Phase 3
- Chronic rhinosinusitis Phase 3
- Cirrhosis of liver Early phase 1
- Coronary artery disorder Phase 3
- COVID-19 Phase 3
- Craniosynostosis Phase 3
- Female reproductive system neoplasm Phase 3
- Femoral neck fracture Phase 3
- Gynecomastia disorder Phase 1
Other linked conditions (21)
- Acute lung injury
- Adolescent idiopathic scoliosis
- Benign prostatic hyperplasia
- Breast cancer
- Carcinoma of duodenum
- Conductive hearing loss disorder
- Congenital heart disease
- Developmental dysplasia of the hip
- Diabetes mellitus
- Duodenum cancer
- Esophageal cancer
- Gastric cancer
- Hemophilia
- Leiomyoma
- Nephrolithiasis
- Obesity disorder
- Osteogenesis imperfecta
- Ovarian cancer
- Placental abruption
- Rosacea
Targets (1)
- PLG Plasminogen inhibitor